Dennis L Panicali

USPTO Granted Patents = 25 (Patent Applications = 1)

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 3.2

ph-index = 12

Forward Citations = 413(Granted Patents)

Location History:

Cambridge, MA (US) (2014)
Acton, MA (US) (1992 - 2015)

Company Filing History:

13 out of 15

Therion Biologics Corporation

patents

9 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

1 out of 1,217

The United States of America As Represented by the Department of Health

patents

4. 1 out of 1

Theriod Biologics, Incorporated

patent

5. 1 out of 1,210

Dana-farber-cancer Institute Inc.

patents

6. 1 out of 2,202

The United States of America As Represented by the Secretary of

8. 2 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2015

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8933041 - System for treating and preventing breast cancer (2015-01-13),

2. 8911991 - Multi-antigen vectors of melanoma (2014-12-16),

3. 8901093 - Custom vectors for treating and preventing pancreatic cancer (2014-12-02),

4. 7771715 - Recombinant vector expressing multiple costimulatory molecules and uses thereof (2010-08-10),

5. 7638134 - Insertion sites in fowlpox vectors (2009-12-29),

6. 7598225 - Generation of immune response to prostate-specific antigen (PSA) (2009-10-06),

7. 7410644 - Recombinant pox virus for immunization against tumor-associated antigens (2008-08-12),

8. 7211432 - Recombinant vector expressing multiple costimulatory molecules and uses thereof (2007-05-01),

9. 7118738 - Recombinant pox virus for immunization against MUC1 tumor-associated antigen (2006-10-10),

10. 6969609 - Recombinant vector expressing multiple costimulatory molecules and uses thereof (2005-11-29),

11. 6699475 - Recombinant pox virus for immunization against tumor-associated antigens (2004-03-02),

12. 6319496 - Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof (2001-11-20),

13. 6165460 - Generation of immune responses to prostate-specific antigen (PSA) (2000-12-26),

14. 6051410 - Self-assembled, defective, nonself-propagating viral particles (2000-04-18),

15. 6001349 - Generation of human cytotoxic T-cells specific for carcinoma (1999-12-14),

Title: Dennis L. Panicali: Pioneering Innovations in Cancer Treatment

Introduction

Dennis L. Panicali, based in Acton, MA, is a distinguished inventor renowned for his contributions to cancer treatment through innovative systems and methods. With an impressive portfolio of 25 patents, Panicali has significantly advanced the field of biomedical research, particularly in the areas of breast cancer and melanoma.

Latest Patents

Among his latest patents, Panicali has developed a "System for treating and preventing breast cancer," which focuses on administering a recombinant poxvirus containing a foreign nucleic acid that encodes at least one breast cancer antigen. This invention aims to provide therapeutic options for individuals at risk of or currently suffering from breast cancer. Another notable patent is for "Multi-antigen vectors of melanoma," which encompasses peptides, polypeptides, and nucleic acids designed to diagnose, treat, or prevent melanoma effectively.

Career Highlights

Panicali's career includes pivotal roles at recognized organizations, including Therion Biologics Corporation and the United States of America, as represented by the Department of Health and Human Services. His work has played a crucial role in the development of novel therapeutic strategies targeting cancer, underscoring his commitment to improving patient outcomes.

Collaborations

Working alongside esteemed colleagues such as Linda R. Gritz and Gail P. Mazzara, Panicali has cultivated a collaborative environment that fosters innovation. These partnerships have been instrumental in enhancing the scope and impact of his research initiatives.

Conclusion

Dennis L. Panicali stands as a prominent figure in the realm of biomedical innovation, with a rich portfolio dedicated to combating cancer. His inventive spirit and collaborative efforts continue to push the boundaries of what's possible in medical treatment, ultimately contributing to a brighter future for patients facing these challenging diseases.

This text is generated by artificial intelligence and may not be accurate.